个人简介
1996年毕业于中山医科大学临床医学系,1999年获得中山大学肿瘤学硕士学位,1999年至今在中山大学肿瘤防治中心内科工作。2006年获得中山大学肿瘤学博士学位。2015-2016年赴美国佛罗里达大学医学院进修。在肺癌治疗领域进行了深入的研究与探索,尤其对肺癌脑转移的临床和基础研究进行了多年的探索,包括药物在血脑屏障的通透性、化疗与脑放射联合治疗肺癌脑转移、肺癌脑转移的靶向治疗、肺癌脑转移的个体化治疗以及肺癌脑转移的机制研究,在相关领域取得较突出的研究和治疗成果。牵头国家自然科学及广东省自然科学基金项目,并与美国FSU医学院合作,开展多项针对肺癌脑转移的转化研究。在晚期肺癌的个体化治疗方面积累了独到的经验。负责及参加了多项肿瘤学省级及国家级研究项目。负责及参加多项国际及国内多中心肿瘤学新药临床研究项目。在国内外杂志发表相关论文50余篇。1996年毕业于中山医科大学,1999年和2006年分别获得肿瘤学硕士学位和博士学位,从事肿瘤临床、教学和科研工作多年。擅长各种恶性肿瘤的内科治疗,尤其是肺癌的化疗、靶向治疗及免疫治疗。
研究领域
从事肿瘤内科治疗的临床工作及抗癌药物研究,特别擅长肺癌的内科治疗(化疗、靶向治疗、免疫治疗)。
近期论文
查看导师新发文章
(温馨提示:请注意重名现象,建议点开原文通过作者单位确认)
1. Xiao-xiao Dinglin, Shu-xiang Ma, Fang Wang, De-lan Li, Jian-zhong Liang, Xin-ru Chen, Qing Liu, Yin-duo Zeng, Li-kun Chen, Establishment of an Adjusted Prognosis Analysis Model for Initially Diagnosed None Small-Cell Lung Cancer with Brain Metastases From Sun Yat-Sen University Cancer Center. Clinical Lung Cancer, 2017, Vol. 18, No. 3, e179-86 2. Xinru Chen,Yu Zhang,Jiabin Lu,Chunwei Xu,Jiangzhong Liang,Fang Wang,Wenyong Sun,Sangao Fang,Jingping Yuan,Huijuan Wang,Hui Wang,Xuewen Liu,Likun Chen, Pulmonary Sarcomatoid Carcinoma with ALK Rearrangement Frequency, Clinical-Pathologic Characteristics, and Response to ALK Inhibitor . Translational Oncology, April 2017, Vol. 10, No. 2, pp.115-120 3. Yin-duo Zeng, Hai Liao, Tao Qin, Li Zhang, Wei-dong Wei, Jian-zhong Liang, Fei Xu, Xiao-xiao Dinglin, Shu-xiang Ma, Li-kun Chen, Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy. Oncotarget. 2015 Apr 10; 6(10): 8366–8376 4. Ji-Jie Huang, Shu-Xiang Ma, Xue Hou, Zhao Wang, Yin-Duo Zeng, Tao Qin, Xiao-Xiao Dinglin, Li-Kun Chen, Toxic epidermal necrolysis related to AP (pemetrexed plus cisplatin) and gefitinib combination thera. Chin J Cancer, 2015, 5(2), 94-98 5. Xiao-xiao Dinglin, Yan Huang, Hui Liu, Yin-duo Zeng, Xue Hou, Li-kun Chen, Pemetrexed and cisplatin combination with concurrent whole brain radiotherapy in patients with brain metastases of lung adenocarcinoma: a single-arm phase II clinical trial. Journal of Neuro-Oncology, May 2013, Volume 112, Issue 3, pp 461–466 6. Zeng Yin-Duo, Zhang Li, Liao Hai, Liang Ying, Xu Fei; Liu Jun-Ling, Dinglin Xiao-Xiao, Chen Li-Kun, Gefitinib Alone or with Concomitant Whole Brain Radiotherapy for Patients with Brain Metastasis from Non-small-cell Lung Cancer: A Retrospective Study. Asian Pac J Cancer Prev , Volume 13, Issue 3, 2012, pp.909-914 7. Chen Li-Kun, Liang Ying, Yang Qun-Ying, Xu Fei, Zhou Ning-Ning, Xu Guang-Chuan, Liu Guo-Zhen, Wei Wei-Dong, Triplet Platinum-based Combination Sequential Chemotherapy Improves Survival Outcome and Quality of Life of Advanced Non-small Cell Lung Cancer Patients. Asian Pac J Cancer Prev, Volume 13, Issue 5, 2012, pp.1863-1867 8. Likun Chen, Youjian He, He Huang, Hai Liao, Weidong Wei, Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study. Medical Oncology, volume 25, issue 2, 2008, pp 161-171 9. Li Kun Chen, He Huang, Hai Liao, Guo Zhen Liu, Yin Duo Zeng, Xiao Xiao Dinglin, Guang Chuan Xu, Wei Dong Wei, Chemotherapy with concurrent brain and thoracic radiotherapy in brain-only metastases of treatment naive small-cell lung cancer: a phase II study. Medical Oncology, volume 29, issue 3, 2012, pp 1687-1692 10. Qin Tao, Zhou Ning-ning, Zeng Yuan-yuan, Dinglin Xiao-xiao, Zhao Yin-duo, Liu Huai, Chen Li-kun, Benefit from thoracic radiotherapy in patients with extensive-disease small-cell lung cancer with elevated lactate dehydrogenase. Onco Targets Ther, 2016 Mar 1;9:1095-103 11. Xin Ru Chen, Jian Zhong Liang, Shu Xiang Ma, Wen Feng Fang, Ning Ning Zhou, Hai Liao, De Lan Li, Li Kun Chen, Consolidation chemotherapy improves progression-free survival in stage III small-cell lung cancer following concurrent chemoradiotherapy: A retrospective study. OncoTargets and Therapy, volume 9, 2016, pp 5729-5736 12. Li DL, Chen XR, Ma SX, Chen LK, Long-lasting response to third-line crizotinib treatment in a patient with non-small cell lung cancer with brain metastases and poor performance status. Thoracic Cancer 2016 Sep;7 (5): 619-622